Nasal Packing Devices Market By Product Type (Absorbable Packs, Non-Absorbable Packs, Balloon Catheters, Hemostatic Dressings); By Application (Epistaxis Management, Postoperative Hemostasis, Trauma-Related Bleeding Control); By End User (Hospitals, Ambulatory Surgical Centers, Emergency Care Clinics); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Segment Revenue Estimation, Forecast, 2026–2032

Nasal Packing Devices Market: Bioresorbable Technologies Reshape Epistaxis Control and Postoperative ENT Care

The Global Nasal Packing Devices Market was valued at USD 208.5 million in 2025 and is projected to reach USD 309.4 million by 2032, growing at a CAGR of 5.8% during 2026–2032, according to Strategic Market Research.

 

Nasal packing devices are used to control bleeding inside the nasal cavity and provide structural support after ENT procedures. By applying direct pressure to bleeding vessels, these products help manage epistaxis that does not respond to basic measures such as compression or cautery. They are also used after septoplasty and functional endoscopic sinus surgery to stabilize tissues, absorb blood and secretions, and support healing.

 

The market is mainly divided into absorbable, non-absorbable, and balloon-based products. Absorbable packs are commonly made from materials such as gelatin, cellulose, oxidized cellulose, or synthetic bioresorbable polymers. These products gradually break down within the nasal cavity, reducing the need for manual removal and improving patient comfort during recovery. Non-absorbable products are generally made from polyvinyl alcohol foam or silicone-based materials. They expand after absorbing fluid and apply sustained pressure to the affected area, although removal by a healthcare professional is usually required.

 

Inflatable balloon systems provide another method of nasal hemostasis. Devices such as Rapid Rhino are positioned within the nasal cavity and inflated to create controlled pressure against bleeding surfaces. These systems are particularly useful for persistent anterior or posterior epistaxis and may also be used after surgery when targeted compression is needed.

 

Several established products are widely used across these categories. Merocel, Express, Rhino Rocket, Ivalon, and Rhinocell are well-known non-absorbable foam-based packing devices. Rapid Rhino uses an inflatable balloon configuration designed for controlled tamponade. Bioresorbable products such as Nasopore, MeroPack, and Medtronic's Novapak gradually clear from the nasal cavity and are increasingly preferred when reduced removal discomfort and better postoperative tissue protection are important.

 

Material innovation is becoming an important area of development in the nasal packing devices market. Chitosan-based and bioactive materials are gaining attention for their hemostatic and antimicrobial properties. These materials are being developed to accelerate clot formation, limit infection risk, and improve performance during both emergency epistaxis management and postoperative care.

 

Drug-eluting and multifunctional packing systems are also advancing. Developers are incorporating anti-inflammatory agents such as mometasone or fluticasone, along with localized anesthetic compounds, into dissolvable polymer matrices. These products are designed to provide mechanical support while also controlling inflammation, pain, and tissue response after functional endoscopic sinus surgery.

 

Smart biomaterials represent another emerging technology area. Temperature- or pH-responsive hydrogels are being designed to change consistency after placement, allowing them to adapt more closely to irregular nasal anatomy and provide localized pressure with less rigidity than conventional packing. Self-expanding and shape-adaptive materials may also reduce tissue adhesion and improve patient comfort during healing.

 

Overall, the nasal packing devices market is moving from traditional removable foam and gauze-based products toward bioresorbable, drug-eluting, and responsive biomaterial technologies. Continued demand for epistaxis treatment, rising ENT surgical volumes, and the need for more comfortable postoperative management are supporting market growth, while advances in chitosan matrices, dissolvable polymers, and smart hydrogels are creating opportunities for next-generation nasal packing products.

 

Which Product Types Are Shaping Nasal Packing Device Demand?

Absorbable Packs accounted for an estimated 36.0% market share in 2025, representing approximately USD 75.1 million, and are projected to grow at a CAGR of 6.6%. Their leading position is supported by increasing use after sinus surgery and preference for materials that gradually clear without conventional pack removal. Evidence comparing absorbable and non-absorbable postoperative packing has also examined benefits around bleeding and adhesion management, while newer postoperative evidence continues to evaluate dressings as part of sinus-surgery recovery. Companies such as Stryker offer NasoPore bioresorbable nasal dressings, while Medtronic markets bioresorbable products including MeroPack and related postoperative products. The segment is estimated to reach about USD 117.2 million by 2032.

Non-Absorbable Packs held an estimated 32.0% share in 2025, equivalent to approximately USD 66.7 million, and are expected to expand at a CAGR of 4.3%. These products retain substantial use because conventional expandable packing remains familiar to emergency physicians and ENT specialists and can provide immediate compression during active bleeding. Growth is slower than absorbable alternatives as patient comfort and removal requirements influence product choice. Providers such as Medtronic continue to maintain Merocel epistaxis packing within their current ENT portfolio, while Innovia Medical's Rhino Rocket uses expandable PVA foam for epistaxis following trauma or surgery. Revenue is estimated at approximately USD 89.7 million by 2032.

Balloon Catheters represented approximately 18.0% of the market in 2025, or USD 37.5 million, and are forecast to grow at a CAGR of 5.9%. Demand is concentrated in cases where clinicians require controlled pressure for more difficult bleeding, including selected posterior epistaxis. FDA records recognize epistaxis balloon devices as a dedicated device classification, supporting their established role within nasal hemorrhage management. For instance, Smith+Nephew's RAPID RHINO portfolio includes inflatable posterior tamponade products alongside its broader epistaxis offering. The segment could reach approximately USD 56.0 million by 2032.

Hemostatic Dressings accounted for an estimated 14.0% share, valued at USD 29.2 million in 2025, and are projected to record the fastest product CAGR of 6.9%. Growth is being supported by increasing interest in materials that combine blood absorption, compression, postoperative tissue separation, and easier clearing. Firms such as Hemostasis offer the PosiSep family for epistaxis and postoperative use, while Smith+Nephew markets dissolvable CMC-based nasal dressings for postoperative rhinology procedures. Revenue is estimated to reach approximately USD 46.5 million by 2032.

 

Which Applications Generate the Highest Nasal Packing Consumption?

Epistaxis Management led the application segment with an estimated 50.0% share in 2025, equal to USD 104.3 million, and is projected to grow at a CAGR of 5.4%. Epistaxis has the closest relationship with direct device consumption because every qualifying bleeding episode can require a new disposable pack. U.S. national data identified 1.2 million emergency-department epistaxis encounters during 2009–2011, while Japan recorded 870,819 gauze-packing procedures during FY2019–2022, averaging 217,705 procedures annually. Key players such as Smith+Nephew, Medtronic, and Innovia Medical maintain products specifically positioned for epistaxis management. The segment is estimated at USD 150.9 million by 2032.

Postoperative Hemostasis accounted for approximately 38.0% of 2025 revenue, or USD 79.2 million, and is expected to grow at the fastest application CAGR of 6.6%. More than 250,000 endoscopic sinus surgeries are performed annually in the U.S., while septoplasty contributes another sizeable procedural pool. The commercial shift toward absorbable dressings also benefits this application because postoperative products are increasingly differentiated by healing support, reduced removal requirements, and patient comfort. Stryker's NasoPore and Medtronic's Novapak are examples of products specifically positioned for nasal and sinus surgery. Postoperative hemostasis revenue is projected at approximately USD 123.5 million by 2032.

Trauma-Related Bleeding Control represented an estimated 12.0% share in 2025, corresponding to USD 25.0 million, and is forecast to grow at a CAGR of 4.9%. Demand comes from nasal injuries requiring immediate mechanical bleeding control and from selected surgical trauma cases rather than overall facial-trauma incidence. For example, Innovia Medical positions Rhino Rocket for epistaxis management following trauma or surgery, while Hemostasis identifies trauma-related bleeding among uses for its PosiSep products. The segment is estimated to reach USD 35.0 million by 2032.

 

Which End Users Account for the Largest Revenue Pool?

Hospitals dominated the market with an estimated 56.0% share in 2025, representing approximately USD 116.8 million, and are projected to expand at a CAGR of 5.4%. Hospitals capture both major purchasing pathways: emergency management of significant epistaxis and postoperative use following ENT procedures. Severe patients may also require escalation to ligation or embolization after conservative treatment, keeping hospitals central to the treatment pathway. Companies such as Medtronic, Smith+Nephew, and Stryker therefore maintain product portfolios suitable for both surgical departments and hospital-based ENT care. Hospital segment revenue is estimated at approximately USD 168.9 million by 2032.

Ambulatory Surgical Centers accounted for approximately 27.0% of market revenue in 2025, or USD 56.3 million, and are forecast to record the fastest end-user CAGR of 6.8%. Sinus and other ENT procedures increasingly fit ambulatory surgical workflows, creating repeat demand for postoperative dressings and hemostatic products. A 2025 study of ambulatory sinus surgery found operating-room time and supply utilization to be meaningful cost components, reinforcing the importance of products that fit efficient outpatient surgical workflows. CMS also maintains a dedicated ASC payment and quality-reporting framework for outpatient procedures. The segment is projected to reach approximately USD 89.0 million by 2032.

Emergency Care Clinics represented an estimated 17.0% share in 2025, equal to USD 35.4 million, and are projected to grow at a CAGR of 5.5%. Their demand is closely tied to acute anterior epistaxis and other bleeding episodes that can be managed without inpatient admission. Products that can be stored easily and used as disposable emergency hemorrhage-control options remain particularly relevant. Providers such as Smith+Nephew and Innovia Medical maintain dedicated epistaxis products suitable for acute-care settings. Revenue is estimated at USD 51.5 million by 2032.

 

How Does Nasal Packing Device Demand Differ by Geography?

North America led the global market with an estimated 39.0% share in 2025, representing USD 81.3 million, and is projected to grow at a CAGR of 5.4%. The region benefits from a large emergency-care system, established ENT surgical activity, reimbursement pathways, and the presence of major suppliers. U.S. sinus surgery alone exceeds 250,000 procedures annually, while medically attended epistaxis provides an additional recurring purchasing base. Current FDA databases also maintain dedicated classifications for epistaxis balloon devices and absorbable ENT polymers. North American revenue is estimated at approximately USD 117.4 million by 2032.

Europe accounted for an estimated 28.0% share in 2025, valued at USD 58.4 million, and is forecast to expand at a CAGR of 5.1%. Established ENT surgery, emergency epistaxis management, and access to absorbable and conventional packing portfolios support regional consumption. Published evidence estimates approximately 22,000 septoplasties annually in the UK, providing one measurable procedural base for postoperative products. Medtronic's current European ENT catalogue includes multiple Merocel epistaxis configurations, while companies such as Stryker maintain bioresorbable dressing portfolios across European markets. Europe is estimated to reach USD 82.8 million by 2032.

Asia-Pacific represented approximately 25.0% of the market in 2025, corresponding to USD 52.1 million, and is projected to be the fastest-growing geography at a CAGR of 7.2%. Japan provides unusually strong evidence of direct device-related utilization, with an average of 217,705 gauze-packing procedures annually during FY2019–2022. Expanding ENT treatment capacity and greater use of postoperative products across large Asian healthcare systems are expected to widen demand beyond conventional gauze and foam products. Companies including Medtronic, Stryker, and specialist ENT suppliers maintain products across Asian markets. Asia-Pacific revenue is estimated at approximately USD 84.8 million by 2032.

Latin America, the Middle East & Africa accounted for an estimated 8.0% share in 2025, equal to USD 16.7 million, and are forecast to grow at a CAGR of 5.6%. Demand is concentrated in hospital emergency departments and larger ENT surgical centers, with conventional packing remaining important where procurement costs influence product choice. Expanding access to specialist ENT care creates room for gradual adoption of absorbable and advanced hemostatic products. The regional segment is projected to reach approximately USD 24.4 million by 2032.

 

What Is Driving the Market Beyond Procedure Volume?

Product preference is shifting toward patient comfort and postoperative workflow. A 2025 meta-analysis comparing Rapid Rhino with Merocel found lower removal-pain scores with Rapid Rhino, while rebleeding differences were not statistically significant. This gives hospitals another basis for differentiating products when hemostatic outcomes are broadly comparable.

Absorbable products also reduce dependence on conventional removal visits. Stryker currently offers multiple bioresorbable nasal dressings with different fragmentation and compression characteristics, while Smith+Nephew offers dissolvable CMC dressings and Medtronic maintains bioresorbable postoperative products.

Growth remains moderated by selective clinical use. Most nosebleeds do not progress to packing, postoperative packing is not used after every ENT operation, and cautery, topical treatments, arterial ligation, and embolization compete with packing at different stages of care. The market therefore grows primarily through qualifying treatment episodes, changes in product mix, and higher adoption of specialized single-use products rather than broad disease prevalence alone.

 

Which Companies Are Leading the Nasal Packing Devices Market?

Medtronic — Global ENT Leader in Nasal Packing & Bioresorbable Solutions

Medtronic participates across conventional and bioresorbable nasal packing through products including Merocel, MeroPack, and Novapak. Novapak is positioned for postoperative nasal/sinus surgery as well as epistaxis, allowing the company to address both principal demand streams.

 

Smith+Nephew — Advanced Epistaxis Control & Dissolvable Postoperative ENT Dressings

Smith+Nephew's RAPID RHINO portfolio provides dedicated epistaxis solutions, while its SINU-FOAM and SINU-KNIT products extend its presence into dissolvable postoperative dressings. This combination gives the company exposure to emergency bleeding management and higher-growth postoperative applications.

 

Stryker — Innovator in Bioabsorbable Nasal Packing Technologies

Stryker focuses strongly on postoperative and bioresorbable products through NasoPore and related ENT dressings. The company's range of fragmentation times and compression characteristics aligns with growing demand for products that avoid conventional removal while providing temporary tissue support.

 

Hemostasis — Specialist in Hemostatic ENT Dressings & Absorbable Splinting Solutions

Hemostasis competes through PosiSep hemostatic dressings and intranasal splints, including products intended for epistaxis, postoperative bleeding, and trauma-related use. Its positioning in absorbable hemostatic technologies gives the company exposure to one of the faster-growing product categories.

 

Innovia Medical — Stronghold in Conventional Epistaxis Management & Emergency ENT Care

Innovia Medical maintains a strong conventional nasal-packing presence through Rhino Rocket and AbsorbENT products. Rhino Rocket targets epistaxis following trauma or surgery, positioning the company across emergency departments, ENT practices, and hospital care.

Competition is increasingly shaped by the balance between reliable bleeding control, patient comfort, absorbability, removal requirements, clinician familiarity, and hospital procurement economics. Suppliers able to serve both acute epistaxis and postoperative ENT surgery are positioned to capture demand across the market's two most important consumption pathways.

 

Nasal Packing Devices Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 208.5 Million
Revenue Forecast in 2032	USD 309.4 Million
Overall Growth Rate	CAGR of 5.8% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	Absorbable Packs, Non-Absorbable Packs, Balloon Catheters, Hemostatic Dressings
By Application	Epistaxis Management, Postoperative Hemostasis, Trauma-Related Bleeding Control
By End User	Hospitals, Ambulatory Surgical Centers, Emergency Care Clinics
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising demand for effective epistaxis management and postoperative ENT hemostasis; increasing adoption of bioresorbable and patient-comfort-oriented nasal packing products; growing ENT and sinus surgery volumes; advances in chitosan-based materials, drug-eluting polymers, and smart hydrogels
Customization Option	Available upon request